Long-term assessment of anti-SARS-CoV-2 antibody levels post-pandemic: Tracking the dynamics after two, three, and four COVID-19 vaccine doses
Authors:
- Fatemeh AshrafianFAFatemeh Ashrafian
- Mostafa Salehi-VaziriMSMostafa Salehi-Vaziri
- Ehsan MostafaviEMEhsan Mostafavi
- Saiedeh Haji MaghsoudiSMSaiedeh Haji Maghsoudi
- Sarah DahmardehSDSarah Dahmardeh
- Anahita BavandABAnahita Bavand
- Ladan MoradiLMLadan Moradi
- Parinaz Tajmehrabi NaminiPNParinaz Tajmehrabi Namini
- Mahsan ZaliMZMahsan Zali
- Zahra TahmasebiZTZahra Tahmasebi
- Mona Sadat LarijaniMLMona Sadat Larijani
- Amitis RamezaniARAmitis Ramezani
Open Access
- 19 January 2025
- journal article
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 18 (3) , 102676
Abstract
No abstract availableKeywords
Funding Information
- Pasteur Institute of Iran
This publication has 24 references indexed in Scilit:
- Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccineHeliyon, 2023
- Safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine (RQ3013) given as the fourth booster following three doses of inactivated vaccines: a double-blinded, randomised, controlled, phase 3b trialeClinicalMedicine, 2023
- Vaccine‐induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 boosterJournal of Medical Virology, 2022
- Long-term serological SARS-CoV-2 IgG kinetics following mRNA COVID-19 vaccine: real-world data from a large cohort of healthcare workersInternational Journal of Infectious Diseases, 2022
- Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialThe Lancet Infectious Diseases, 2022
- Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challengesMetabolism Open, 2022
- A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challengesVirusDisease, 2022
- Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of ConcernCell Research, 2021
- Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort studyClinical Microbiology and Infection, 2021
- Adaptive immunity to SARS-CoV-2 and COVID-19Cell, 2021